BACKGROUND: Cytokine stimulation of B-cell proliferation may be an important causative mechanism for acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL). The Epstein-Barr virus (EBV) may be a co-factor, particularly for primary central nervous system (CNS) tumors, which are uniformly EBV-positive in the setting of AIDS. Thus, we examined associations of genetic variation in IL10 and related cytokine-signaling molecules (IL10RA, CXCL12, IL13, IL4, IL4R, CCL5 and BCL6) with AIDS-related NHL risk and evaluated differences between primary CNS and systemic tumors. PATIENTS AND MATERIALS: We compared 160 Multicenter AIDS Cohort Study (MACS) participants with incident lymphomas, of which 90 followed another AIDS diagnosis, to HIV-1-seropositive controls matched on duration of lymphoma-free survival post-HIV-1 infection (N = 160) or post-AIDS diagnosis (N = 90). We fit conditional logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Carriage of at least one copy of the T allele for the IL10 rs1800871 (as compared to no copies) was associated with decreased AIDS-NHL risk specific to lymphomas arising from the CNS (CC vs. CT/TT: OR = 0.3; 95% CI 0.1, 0.7) but not systemically (CC vs. CT/TT: OR = 1.0; 95% CI 0.5, 1.9) (Pheterogeneity = 0.03). Carriage of two copies of the 'low IL10' haplotype rs1800896_A/rs1800871_T/rs1800872_A was associated with decreased lymphoma risk that varied by number of copies (Ptrend = 0.02). None of the ORs for the other studied polymorphisms was significantly different from 1.0. CONCLUSION: Excessive IL10 response to HIV-1 infection may be associated with increased risk of NHL, particularly in the CNS. IL10 dysregulation may be an important causative pathway for EBV-related lymphomagenesis.
BACKGROUND: Cytokine stimulation of B-cell proliferation may be an important causative mechanism for acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL). The Epstein-Barr virus (EBV) may be a co-factor, particularly for primary central nervous system (CNS) tumors, which are uniformly EBV-positive in the setting of AIDS. Thus, we examined associations of genetic variation in IL10 and related cytokine-signaling molecules (IL10RA, CXCL12, IL13, IL4, IL4R, CCL5 and BCL6) with AIDS-related NHL risk and evaluated differences between primary CNS and systemic tumors. PATIENTS AND MATERIALS: We compared 160 Multicenter AIDS Cohort Study (MACS) participants with incident lymphomas, of which 90 followed another AIDS diagnosis, to HIV-1-seropositive controls matched on duration of lymphoma-free survival post-HIV-1 infection (N = 160) or post-AIDS diagnosis (N = 90). We fit conditional logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Carriage of at least one copy of the T allele for the IL10rs1800871 (as compared to no copies) was associated with decreased AIDS-NHL risk specific to lymphomas arising from the CNS (CC vs. CT/TT: OR = 0.3; 95% CI 0.1, 0.7) but not systemically (CC vs. CT/TT: OR = 1.0; 95% CI 0.5, 1.9) (Pheterogeneity = 0.03). Carriage of two copies of the 'low IL10' haplotype rs1800896_A/rs1800871_T/rs1800872_A was associated with decreased lymphoma risk that varied by number of copies (Ptrend = 0.02). None of the ORs for the other studied polymorphisms was significantly different from 1.0. CONCLUSION: Excessive IL10 response to HIV-1 infection may be associated with increased risk of NHL, particularly in the CNS. IL10 dysregulation may be an important causative pathway for EBV-related lymphomagenesis.
Authors: R H Lyles; A Muñoz; T E Yamashita; H Bazmi; R Detels; C R Rinaldo; J B Margolick; J P Phair; J W Mellors Journal: J Infect Dis Date: 2000-03 Impact factor: 5.226
Authors: A Cingolani; R Gastaldi; L Fassone; F Pierconti; M L Giancola; M Martini; A De Luca; A Ammassari; C Mazzone; E Pescarmona; G Gaidano; L M Larocca; A Antinori Journal: J Clin Oncol Date: 2000-10-01 Impact factor: 44.544
Authors: L M Larocca; D Capello; A Rinelli; S Nori; A Antinori; A Gloghini; A Cingolani; A Migliazza; G Saglio; S Cammilleri-Broet; M Raphael; A Carbone; G Gaidano Journal: Blood Date: 1998-08-01 Impact factor: 22.113
Authors: Lindsay M Morton; Sophia S Wang; Wendy Cozen; Martha S Linet; Nilanjan Chatterjee; Scott Davis; Richard K Severson; Joanne S Colt; Mohammad A Vasef; Nathaniel Rothman; Aaron Blair; Leslie Bernstein; Amanda J Cross; Anneclaire J De Roos; Eric A Engels; David W Hein; Deirdre A Hill; Linda E Kelemen; Unhee Lim; Charles F Lynch; Maryjean Schenk; Sholom Wacholder; Mary H Ward; Shelia Hoar Zahm; Stephen J Chanock; James R Cerhan; Patricia Hartge Journal: Blood Date: 2008-09-16 Impact factor: 22.113
Authors: Erin C Peckham-Gregory; Dharma R Thapa; Jeremy Martinson; Priya Duggal; Sudhir Penugonda; Jay H Bream; Po-Yin Chang; Sugandha Dandekar; Shen-Chih Chang; Roger Detels; Otoniel Martínez-Maza; Zuo-Feng Zhang; Shehnaz K Hussain Journal: Cancer Epidemiol Date: 2016-10-01 Impact factor: 2.984
Authors: Daniel C Beachler; Lan L Gellert; Lisa P Jacobson; Richard F Ambinder; Elizabeth C Breen; Otoniel Martínez-Maza; Charles S Rabkin; Charles C Rabkin; Richard A Kaslow; Gypsyamber D'Souza Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: David Eric Ouedraogo; Alain Makinson; Nils Kuster; Nicolas Nagot; Pierre-Alain Rubbo; Karine Bollore; Vincent Foulongne; Guillaume Cartron; Daniel Olive; Jacques Reynes; Jean-Pierre Vendrell; Edouard Tuaillon Journal: J Clin Immunol Date: 2012-08-23 Impact factor: 8.317
Authors: Elena Vendrame; Shehnaz K Hussain; Elizabeth Crabb Breen; Larry I Magpantay; Daniel P Widney; Lisa P Jacobson; Daina Variakojis; Emilee R Knowlton; Jay H Bream; Richard F Ambinder; Roger Detels; Otoniel Martínez-Maza Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-11-12 Impact factor: 4.254